Edition:
United Kingdom

Michael Erman

NHS England, Biogen reach deal on pricey drug for deadly disorder

15 May 2019

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

15 May 2019

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

U.S. government to require drugmakers to show prices in TV ads

08 May 2019

The Trump administration on Wednesday said it will require drugmakers to disclose the list price of prescription drugs in direct-to-consumer television advertisements, part of the government's efforts to lower costs for U.S. consumers.

Pfizer gets U.S. approval for $225,000 a year heart drug

06 May 2019

NEW YORK The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Merck steps up U.S. measles vaccine production with increased demand

01 May 2019

NEW YORK Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.

Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

30 Apr 2019

Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

25 Apr 2019

NEW YORK U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Bristol-Myers says shareholders vote to approve Celgene takeover

12 Apr 2019

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

World News